Number of recent infections.

a<p>Number of samples classified as recent out of 152 total specimens.</p><p>Number of recent infections.</p

Correlation between plasma and DBS.

<p>The normalized MFI values (n) and avidity index (a) for plasma versus DBS were compared for all specimens. The solid line represents the linear trend line for all data points.</p

Correlation in antibody reactivity between plasma and DBS.

a<p>Inter-assay variation, as measured by repeat testing of know Incident/Prevalent controls. CV is representative of median values for standards.</p>b<p>Median value for all samples, comparing plasma and DBS values.</p><p>Correlation in antibody reactivity between plasma and DBS.</p

Correlation with site-prepared DBS.

<p>Correlation with site-prepared DBS.</p

Intra-assay variability.

a<p>Calculated based on MFI values of intra-assay sample replicates.</p><p>Intra-assay variability.</p

CDC versus field DBS.

<p>The normalized MFI values and avidity index were compared for CDC versus field-prepared DBS. The solid lines represent the linear trend lines.</p

Characterization of the HIV-1-specific Bio-Plex.

a<p>Algorithm cutoffs are listed as the number of analytes that must measure above each analyte-specific cutoff to be considered long-term over the total number of analytes in the algorithm.</p>b<p>Relative % difference from actual population incidence.</p

Bio-Plex assay performance on subtype C specimens.

<p>Bio-Plex assay performance on subtype C specimens.</p

Longitudinal HIV-1-specific antibody responses.

<p>The normalized values (A) and avidity index (B), as measured by the Bio-Plex assay, for longitudinal seroconverters were plotted over days since seroconversion. Gray diamonds indicate individual data points and solid black circles represent the curve fit for each graph. Dashed red lines represent the half maximal response of the curve and lower 99.9% confidence limits of the estimate, while the solid black line represents the selected cutoff.</p

Impact of disease progression and antiretroviral use on false-recent rates.

a<p>Includes entire MSM cohort.</p